<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00212381</url>
  </required_header>
  <id_info>
    <org_study_id>9218</org_study_id>
    <nct_id>NCT00212381</nct_id>
    <nct_alias>NCT00206804</nct_alias>
  </id_info>
  <brief_title>Oral Diindolylmethane (DIM) for the Treatment of Cervical Dysplasia</brief_title>
  <official_title>Diindolylmethane (DIM) Dietary Supplementation: A Nonsurgical Treatment for Cervical Intraepithelial Neoplasia (CIN)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York Presbyterian Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York Presbyterian Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if the use of oral Diindolylmethante (DIM), a marketed cruciferous vegetable
      based dietary supplement (Bioresponse-DIM), is associated with the regression of cervical
      dysplasia in otherwise healthy women.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To determine if the use of oral Diindolylmethane (DIM), a marketed cruciferous vegetable
      based dietary supplement (BioResponse-DIMÂ®), is associated with the regression of cervical
      dysplasia in otherwise healthy women. Additionally, the study aims to see how the use of the
      BioResponse-DIM supplement correlates with cervical HPV colonization, and to asses the
      tolerability of daily DIM supplementation
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2000</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">January 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized double blind intervention trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>central pharmacy dispenses based on sealed randomization table</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Measure the regression of CIN in women by cytology, colposcopy, and biopsy,</measure>
    <time_frame>3 months</time_frame>
    <description>To determine if oral DIM is effective in promoting the regression of CIN in women</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HPV colonization by commercial ELIZA test</measure>
    <time_frame>3 months</time_frame>
    <description>To correlate the response to DIM with HPV colonization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events reported by subjects and lab abnormalities i.e. CBC and SMA20</measure>
    <time_frame>one year</time_frame>
    <description>To assess for any adverse effects of oral DIM in women</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">62</enrollment>
  <condition>Cervical Dysplasia</condition>
  <arm_group>
    <arm_group_label>oral DIM (Active agent)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2mg/kg/day po of DIM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Red rice bran (Placebo)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>this agent is not generally thought to be active but may be</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>di indolylmethane (DIM)</intervention_name>
    <description>This is the agent being studies. Similar agents have been reported to have potential activity.</description>
    <arm_group_label>oral DIM (Active agent)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Red rice bran</intervention_name>
    <description>this will act as the active comparator. The sponsor provided this as the &quot;placebo&quot; arm since it is a filler component of their DIM capsules</description>
    <arm_group_label>Red rice bran (Placebo)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Non pregnant women greater than or equal to 18 years of age able to consent

          -  CIN II or III confirmed by histology

          -  Karnofsky performance status &gt;= 80

          -  No prior treatment for dysplasia in the past 4 months

        Exclusion Criteria:

          -  Incompletely visible lesion

          -  Diethylstilbestrol (DES) exposure

          -  HIV seropositive
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe Del Priore, M.D., M.P.H.</last_name>
    <role>Study Director</role>
    <affiliation>NY Downtown Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alan Arslan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>NYU School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Del Priore G, Gudipudi DK, Montemarano N, Restivo AM, Malanowska-Stega J, Arslan AA. Oral diindolylmethane (DIM): pilot evaluation of a nonsurgical treatment for cervical dysplasia. Gynecol Oncol. 2010 Mar;116(3):464-7. doi: 10.1016/j.ygyno.2009.10.060. Epub 2009 Nov 24.</citation>
    <PMID>19939441</PMID>
  </results_reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>March 27, 2017</last_update_submitted>
  <last_update_submitted_qc>March 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York Presbyterian Hospital</investigator_affiliation>
    <investigator_full_name>Giuseppe Del Priore</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>cervical dysplasia, diindolylmethane, pap smear</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
    <mesh_term>Uterine Cervical Dysplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>3,3'-diindolylmethane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

